The effectiveness of Pre-Exposure Prophylaxis (PrEP) for reducing HIV transmission is strongly dependent on adherence, which is influenced by individual, social, and structural factors. We propose a social network-based intervention to promote PrEP adherence among transgender women (TW) in Lima, Peru: 1) Formative research. To optimize content for a PrEP adherence intervention, we will conduct semi- structured interviews and focus groups. Results will be used to refine the PrEP adherence intervention. 2) To conduct an open evaluation of a social network-based PrEP adherence intervention for TW in Peru. The intervention model will be piloted with a small group of 5-10 TW. Data will be used to finalize the study design and assessment tools for a pilot randomized controlled trial (RCT). 3) To conduct a pilot RCT of a social network-based PrEP adherence intervention for TW in Peru. We plan to randomize 8 social network-based clusters of TW that to either a network-based PrEP adherence intervention or standardized PrEP adherence counseling. The primary outcome will be PrEP adherence. The intervention will use a combination of individual counseling, group workshops, social media-based network interactions, and practical support tools to promote PrEP adherence among TW. Individual Counseling: Participants will complete two biweekly counseling sessions addressing PrEP use and HIV prevention. The goals of individual counseling are to introduce PrEP as an HIV prevention tool and address basic issues of PrEP adherence as part of a comprehensive HIV prevention strategy. Group Workshops. Group workshops will establish a common understanding of PrEP as a central component of comprehensive HIV prevention, address the importance of PrEP adherence, develop practical strategies to support adherence, and generate and maintain norms of HIV prevention and PrEP adherence within the peer group. Biweekly maintenance meetings will address ongoing issues related to PrEP use and adherence. Social Network Interactions. The social network component of the intervention will include structured social media platforms to educate, motivate, and promote discussions of PrEP adherence within the participant network, unstructured participant-generated interactions to articulate and reinforce newly developed social norms within the network, and practical tools to support daily adherence. PrEP Use. Participants will be provided with daily Truvada for the 6-month study period. Assessment Procedures, Timing and Measures. There will be three major assessment points: baseline, short-term outcome (3 month), and long-term outcome (6 month). The primary outcome of the intervention will be a comparison of PrEP adherence in the intervention and control groups. Findings will be used to support an NIH-funded R01 proposal using social networks of TW and social media technologies to generate, implement, and reinforce new social norms of PrEP adherence, sexual risk behavior, and HIV prevention.

Public Health Relevance

Pre-exposure prophylaxis (PrEP) is an important new tool for HIV prevention, but is highly dependent on patient adherence. Our study the uses social networks of transgender women in Peru as a framework to promote PrEP adherence in socially marginalized communities at high risk for HIV infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Planning Grant (R34)
Project #
5R34MH104072-03
Application #
9119194
Study Section
Special Emphasis Panel (ZMH1-ERB-M (02))
Program Officer
Stirratt, Michael J
Project Start
2014-08-01
Project End
2017-07-31
Budget Start
2016-08-01
Budget End
2017-07-31
Support Year
3
Fiscal Year
2016
Total Cost
$141,615
Indirect Cost
$18,663
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Reisner, Sari L; Perez-Brumer, Amaya G; McLean, Sarah A et al. (2017) Perceived Barriers and Facilitators to Integrating HIV Prevention and Treatment with Cross-Sex Hormone Therapy for Transgender Women in Lima, Peru. AIDS Behav 21:3299-3311
Satcher, Milan F; Segura, Eddy R; Silva-Santisteban, Alfonso et al. (2017) Partner-Level Factors Associated with Insertive and Receptive Condomless Anal Intercourse Among Transgender Women in Lima, Peru. AIDS Behav 21:2439-2451
Reisner, Sari L; Deutsch, Madeline B; Bhasin, Shalender et al. (2016) Advancing methods for US transgender health research. Curr Opin Endocrinol Diabetes Obes 23:198-207
Perez-Brumer, Amaya G; Oldenburg, Catherine E; Reisner, Sari L et al. (2016) Towards 'reflexive epidemiology': Conflation of cisgender male and transgender women sex workers and implications for global understandings of HIV prevalence. Glob Public Health 11:849-65
Perez-Brumer, Amaya G; Oldenburg, Catherine E; Segura, Eddy R et al. (2016) Anonymous partnerships among MSM and transgender women (TW) recently diagnosed with HIV and other STIs in Lima, Peru: an individual-level and dyad-level analysis. Sex Transm Infect 92:554-557
Blair, CherĂ­e S; Segura, Eddy R; Perez-Brumer, Amaya G et al. (2016) Sexual Orientation, Gender Identity and Perceived Source of Infection Among Men Who Have Sex with Men (MSM) and Transgender Women (TW) Recently Diagnosed with HIV and/or STI in Lima, Peru. AIDS Behav 20:2178-2185
Reisner, Sari L; Radix, Asa; Deutsch, Madeline B (2016) Integrated and Gender-Affirming Transgender Clinical Care and Research. J Acquir Immune Defic Syndr 72 Suppl 3:S235-42
Gamarel, Kristi E; Reisner, Sari L; Darbes, Lynae A et al. (2016) Dyadic dynamics of HIV risk among transgender women and their primary male sexual partners: the role of sexual agreement types and motivations. AIDS Care 28:104-11
Poteat, Tonia; Scheim, Ayden; Xavier, Jessica et al. (2016) Global Epidemiology of HIV Infection and Related Syndemics Affecting Transgender People. J Acquir Immune Defic Syndr 72 Suppl 3:S210-9
Reisner, Sari L; Murchison, Gabriel R (2016) A global research synthesis of HIV and STI biobehavioural risks in female-to-male transgender adults. Glob Public Health 11:866-87